In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Scoops Up PercuSurge

Executive Summary

The news that PercuSurge, the leader in emboli collection/protection devices, had been purchased by Medtronic caused some medical device executives to shake their heads in disbelief. Many had viewed a much-anticipated PercuSurge IPO as one of the most promising in the device industry in years, and they were confident that the device itself has the potential to be a blockbuster. That blockbuster potential, combined with the $225 million price tag, made it seem, frankly, as if PercuSurge had given up too early and too easily. But executives close to PercuSurge defended the company's move while affirming the long-term potential of the device.
Advertisement

Related Content

Turning Around Medtronic Vascular
Keeping Leadership Real: An Interview with Bill George
Embolic Protection: Better Outcomes Not Enough
Embolic Protection: Better Outcomes Not Enough
Embolic Protection: Working the Guidewire With a Net
The Sell/Go Public Dilemma for Device Companies

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel